NEW YORK (GenomeWeb) – Turning Point Therapeutics and Almac Diagnostic Services today announced approval by the US Food and Drug Administration of an investigational device exemption for use of an Almac diagnostic assay to determine whether cancer patients are eligible to enroll in a Phase II clinical study.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.